[Narcotic withdrawal syndrome. Therapeutic methods].
D015670:Acupuncture Therapy; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000698:Analgesia; D001921:Brain / Q000503:physiopathology; D002491:Central Nervous System Agents / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D004723:Endorphins / Q000009:adverse effects; D006801:Humans; D008691:Methadone / Q000627:therapeutic use; D009270:Naloxone / Q000627:therapeutic use; D009271:Naltrexone / Q000627:therapeutic use; D009294:Narcotics / Q000009:adverse effects*; D011957:Receptors, Opioid / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D019966:Substance-Related Disorders / Q000209:etiology
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D002491:Central Nervous System Agents; D004723:Endorphins; D009294:Narcotics; D011957:Receptors, Opioid; D009270:Naloxone; D009271:Naltrexone; D003000:Clonidine; D008691:Methadone
Sindrome de abstinencia a narcóticos. Medidas terapéuticas.